Beyond Air Reports Revenue Growth and Reduced Net Losses in Q2 Fiscal 2025

Beyond Air, Inc. reported its financial results for the second quarter of fiscal 2025, revealing a significant increase in revenue and a reduction in net losses compared to the same period last year. For the three months ended September 30, 2025, the company generated revenues of $1.8 million, up from $798,000 in the prior year, while total revenues for the six-month period reached $3.6 million, compared to $1.5 million in the same timeframe last year. Despite the revenue growth, the company incurred a gross loss of $298,000 for the quarter, an improvement from a gross loss of $1.1 million in the previous year.

The company’s operating expenses also decreased significantly, with total operating expenses for the three months ending September 30, 2025, amounting to $7.4 million, down from $11.7 million in the same quarter of 2024. This reduction was primarily driven by lower research and development costs, which fell to $2.5 million from $4.6 million, and a decrease in selling, general, and administrative expenses, which dropped to $4.9 million from $7.2 million. The net loss attributable to Beyond Air, Inc. for the quarter was $7.9 million, or $1.25 per share, compared to a net loss of $13.4 million, or $5.67 per share, in the prior year.

Strategically, Beyond Air has made significant strides in expanding its product offerings and market presence. The company continues to focus on its LungFit® platform, which includes the LungFit® PH device, approved by the FDA for treating persistent pulmonary hypertension in newborns. The company has also received CE mark approval for the device in Europe and is actively pursuing regulatory approvals in additional international markets, including Australia and several Southeast Asian countries. Furthermore, Beyond Air has entered into new distribution agreements in various regions, which are expected to contribute to revenue growth in fiscal 2026 and beyond.

Operationally, Beyond Air has seen an increase in customer engagement, with a notable rise in the number of hospitals contracting for the LungFit® PH device. The company reported a cash position of $9.7 million as of September 30, 2025, an increase from $4.7 million at the end of the previous fiscal period. This improvement in liquidity is attributed to successful financing activities, including proceeds from the sale of common stock and the exercise of warrants. However, the company anticipates needing additional funding within the next year to support ongoing operations and product development.

Looking ahead, Beyond Air remains focused on advancing its product pipeline and expanding its market reach. The company expects to continue incurring net losses and significant cash outflows as it invests in research and development and commercialization efforts. Management is optimistic about securing additional financing to support its strategic initiatives and believes that the successful launch of the LungFit® PH device will be critical to achieving long-term financial stability and growth.